Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.52 |
| ▸ | CNR2 | P34972 | 9/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260560 | 0.96 | CNR1 (0.57) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4270104 | 0.88 | CNR1 (0.49) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4262421 | 0.84 | CNR1 (0.56) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4264936 | 0.83 | CNR1 (0.56) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4261619 | 0.83 | CNR1 (0.52) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4267613 | 0.79 | CNR2 (0.53) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4274011 | 0.79 | CNR2 (0.56) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4265524 | 0.79 | CNR1 (0.63) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL13589104 | 0.78 | CNR1 (0.65) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL4267555 | 0.77 | CNR1 (0.47) | CNR1CNR2NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054376-A1 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION | 2009-02-26 | — | — | US | claimed |
| EP-1885709-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | Pharmos Corporation (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2006129318-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION (US) | 2006-12-07 | — | — | WO | claimed |
| US-20090054376-A1 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION | 2009-02-26 | — | — | US | disclosed |
| EP-1885709-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | Pharmos Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006129318-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054376-A1 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | CNR2, CNR1, TRPV1 | CNR1 2/4885CNR2 1/4885NR1I2 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.